Patients with diabetic macular edema treated with brolucizumab 6 mg demonstrated noninferiority in change in best corrected visual acuity compared with patients who received aflibercept 2 mg, according to the results of a phase 3 study.
Novartis released data from the phase 3 KESTREL study, which assessed the safety and efficacy of Beovu (brolucizumab) 3 mg and 6 mg in DME. Patients in the brolucizumab 6 mg arm experienced noninferiority in change in BCVA at 1 year from baseline compared with patients treated with 2 mg of aflibercept. In addition, (Read more...)
Uncategorized